Category - Developments

Developments

MindMed collaborators present positive Phase 2 data of LSD in anxiety

Prof. Matthias Liechti and Dr. Friederike Holze, Mind Medicine’s (NASDAQ:MNMD; NEO:MMED) collaborators at University Hospital Basel presented positive topline data from a Phase 2 placebo-controlled investigator...

May 11, 2022

Developments

Profound Medical nearly doubles Q1 revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) posted revenue of $1.4-million in the first quarter, up 92%, from $711,000 in the year earlier quarter. In the latest period, the company generated $1.02-million from recurring...

May 9, 2022

Developments

Athira Pharma extends open label extension AD studies with fosgonimeton

Athira Pharma (NASDAQ:ATHA) is extending the length of the current open label extension study for its Phase 3 LIFT-AD and Phase 2 ACT-AD studies of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s...

May 9, 2022

Developments

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Rani Therapeutics (NASDAQ:RANI) took top honors for its RaniPill capsule in the health category of Fast Company‘s 2022 World Changing Ideas. The RaniPill capsule is about the size of a standard fish oil pill...

May 3, 2022

Developments

Hepion Pharma, HepQuant in clinical collaboration for Phase 2b NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) entered into a clinical collaboration with HepQuant, a closely-held Denver company with novel, proprietary investigational technology for evaluating liver function and health in...

May 3, 2022

Developments

Profound Medical gets high marks from Cowen on KOL webinar for TULSA-PRO

A key opinion leader highlighted the numerous technology advancements and clinical advantages of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO treatment of prostate diseases at a company hosted clinical education...

May 2, 2022

Developments

Limaca Medical receives FDA breakthrough device designation

The FDA granted closely-held Limaca Medical of Israel breakthrough device designation for its Precision-GI endoscopic ultrasound biopsy product. The Precision-GI device is designed to obtain tumor tissue within or...

May 2, 2022

Developments

Zucara Therapeutics secures additional funding to develop ZT-01 for T2D

Closely-held Zucara Therapeutics received second grants from each of GlycoNet and Mitacs to support the development of ZT-01 for the treatment of insulin-induced hypoglycemia in people with Type 2 diabetes. “GlycoNet’s...

May 2, 2022

Developments

First Wave BioPharma fails Phase 2 GI trial to clear SARS-CoV-2

The efficacy endpoint of First Wave BioPharma’s (NASDAQ:FWBI) Phase 2 RESERVOIR trial with FW-COV did not demonstrate statistical significance, compared to placebo, in removing the SARS-CoV-2 virus from the digestive...

May 2, 2022

Developments

Annovis Bio in pact with the National Institute on Aging

Annovis Bio (NYSE:ANVS) entered a cooperative research and development agreement with the NIH’s National Institute on Aging to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived...

April 29, 2022

Category - Developments

Subscribe